VOLUME 18 | NUMBER 2 | FEBRUARY 2012 nature medicine t e c h n i c a l r e p o r t s Glutamate, a major neurotransmitter in the brain, shows a pHand concentration-dependent chemical exchange saturation transfer effect (GluCEST) between its amine group and bulk water, with potential for in vivo imaging by nuclear magnetic resonance. GluCEST asymmetry is observed ~3 p.p.m. downfield from bulk water. Middle cerebral artery occlusion in the rat brain resulted in an ~100% elevation of GluCEST in the ipsilateral side compared with the contralateral side, predominantly owing to pH changes. In a rat brain tumor model with blood-brain barrier disruption, intravenous glutamate injection resulted in a clear elevation of GluCEST and a similar increase in the proton magnetic resonance spectroscopy signal of glutamate. GluCEST maps from healthy human brain were also obtained. These results demonstrate the feasibility of using GluCEST for mapping relative changes in glutamate concentration, as well as pH, in vivo. Contributions from other brain metabolites to the GluCEST effect are also discussed.
Glutamate, a major neurotransmitter in the brain, shows a pHand concentration-dependent chemical exchange saturation transfer effect (GluCEST) between its amine group and bulk water, with potential for in vivo imaging by nuclear magnetic resonance. GluCEST asymmetry is observed ~3 p.p.m. downfield from bulk water. Middle cerebral artery occlusion in the rat brain resulted in an ~100% elevation of GluCEST in the ipsilateral side compared with the contralateral side, predominantly owing to pH changes. In a rat brain tumor model with blood-brain barrier disruption, intravenous glutamate injection resulted in a clear elevation of GluCEST and a similar increase in the proton magnetic resonance spectroscopy signal of glutamate. GluCEST maps from healthy human brain were also obtained. These results demonstrate the feasibility of using GluCEST for mapping relative changes in glutamate concentration, as well as pH, in vivo. Contributions from other brain metabolites to the GluCEST effect are also discussed.
Glutamate and γ-aminobutyric acid (GABA) are the major excitatory and inhibitory neurotransmitters, respectively, in the brain and are likely involved in nearly all signal processing functions of the central nervous system (CNS) and altered in many CNS diseases [1] [2] [3] [4] . Magnetic resonance imaging (MRI) is a noninvasive imaging technique that provides exquisite structural detail, but current MRI methods are not capable of imaging the distribution of neurotransmitters in brain (Supplementary Note).
Proton magnetic resonance spectroscopy ( 1 H MRS) can detect several neurotransmitter signature groups using a variety of techniques [5] [6] [7] [8] [9] [10] . However, 1 H MRS techniques require long acquisition times and have poor spatial resolution. Here we describe a new MRI technique for imaging glutamate (R.R., K.C., M.H., A.S., F.K. and H.H., unpublished data) based on its chemical exchange saturation transfer (CEST) effect [11] [12] [13] [14] [15] . GluCEST provides markedly higher spatial and temporal resolution compared with 1 H MRS. The CEST effect from amide and hydroxyl protons from different amino acids, proteins and other molecules 12, 16, 17 have previously been exploited to measure pH in vivo 18, 19 , glycogen in the liver 20 , glycosaminoglycans in cartilage 21 , gene expression in vivo 22 and myo-inositol in brain 23 , but no prior studies have used the CEST effect of amine protons to image glutamate in vivo.
Here the pH and concentration dependence of GluCEST is first demonstrated in vitro at 37 °C. Second, the feasibility of measuring GluCEST in vivo from rat brain with and without focal ischemia is shown. Third, changes in GluCEST and glutamate 1 H MRS in response to exogenous injection of glutamate in a rat brain tumor model are compared. Finally, the feasibility of mapping the glutamate signal from healthy human brain in vivo is demonstrated at 7 Tesla (7T), an ultrahigh-field whole-body imaging scanner. The potential contributions to GluCEST from other brain metabolites, as well as the advantages and shortcomings of this approach, are also discussed.
RESULTS

Phantom studies
The z-spectra of 10 mM glutamate solutions at varying pHs (phantoms) demonstrate that at lower pHs (pH < 6.0), the CEST peak of glutamate is sharper and centered around 3 p.p.m. higher frequency from the bulk water resonance (absolute chemical shift, 7.7 p.p.m.) (Fig. 1a) . The z-spectral asymmetry plots (Fig. 1b) gave a broad CEST effect ranging from 1 to 4 p.p.m. relative to bulk water resonance. Whereas the GluCEST asymmetry plots from low pH solutions showed clear peaks centered at ~3.00 p.p.m., the peak position of asymmetry plots from higher pH solutions (pH >6.0) gradually moved toward that of water resonance. At pH 7, the maximum of the asymmetry plot occurred at ~1.2 p.p.m., and its amplitude was ~100% higher than at 3 p.p.m. This is the well known phenomenon of intermediate-to fast-exchange (k ≥ ∆ω)-mediated chemical shift averaging. Despite the shift in peak position at pH 7, all of our studies reported here used 3 p.p.m. as the GluCEST resonance saturation frequency to maintain consistency.
Because of non-steady-state experimental conditions, we analyzed the sensitivity of GluCEST by solving numerical simulations of full Bloch-McConnell equations 24 using the experimental parameters from these studies. We found an excellent agreement between the experimental z-spectral asymmetry curves and numerically simulated ones. Because the intracellular pH in the brains of normal healthy volunteers is reported to be ~7.0 (ref. 25) , the GluCEST contrast at this pH is the most relevant for in vivo imaging. On the basis of the fitted z-spectral asymmetry curve from simulations (Fig. 1b) , the amine-proton exchange rate (k) in a 10 mM glutamate solution (pH 7.0) at 37 °C was estimated to be in the range of 5,500 ± 500 s -1 . This is comparable to the chemical shift difference (∆ω) at 7T (∆ω = 5,700 rad s -1 ); thus, GluCEST imaging is feasible at 7T, as well as at higher field strengths.
For the experimental saturation parameters used here, GluCEST increased gradually from pH 3 to pH 6 and then sharply decreased from pH 6 to 8. The largest GluCEST observed at pH 6 is probably caused by the estimated reduced exchange rate of amine protons with the bulk water. GluCEST varies linearly with pH in the physiological range (pH 6.0-7.4) (Fig. 1c) . There is a ~700-fold sensitivity advantage of GluCEST over conventional 1 H MRS at physiological concentration and temperature ( Fig. 1d-g ). This sensitivity amplification should make it feasible to detect relatively small changes in glutamate levels at high resolution (voxel size of 0.02 cc).
The GluCEST effect is linearly proportional to the glutamate concentration in the physiological range at pH 7 (Fig. 2a) . With the imaging parameters used here, an ~0.6% CEST effect increase per mM glutamate was observed (Fig. 2b) . The GluCEST effect increased with peak radiofrequency (RF) field (B 1 ) amplitude and saturation pulse duration, demonstrating that it is possible to obtain higher GluCEST effects (>1% per mM glutamate) (Fig. 2c) .
Whereas it is possible to achieve a higher GluCEST sensitivity by using higher B 1 , the imaging parameters chosen here were constrained by the exchange rate differences between phantoms and in vivo tissue, as well as RF-specific absorption rate (SAR) issues in human studies at 7T. As SAR is proportional to the B 1 2 , and the square of the static magnetic field (B 0 2 ), the allowed B 1 amplitude at 7T is limited for human imaging.
Potential contributions from other brain metabolites
The major metabolites in the brain visible with 1 H MRS at physiological concentrations are N-acetyl aspartate, choline, myo-inositol, creatine, glutamine, taurine, aspartate, glutamate and GABA. After investigating the CEST properties from each of these metabolites in phantoms, we found that, with the experimental parameters used here, except for a small contribution from GABA and creatine, all other metabolites contributed negligible CEST effects to GluCEST (Fig. 2d,e) . Of these metabolites, N-acetyl aspartate has an amide 
Rat studies
In healthy rat brain, the gray matter and white matter were clearly separated in the GluCEST, with a contrast ratio of ~1.6 ( Fig. 3a-d) .
The glutamate amine exchange rate measured in healthy rat brain was ~2,000 ± 500 s -1 (Supplementary Methods), which is well within the slow to intermediate exchange regime at 7T. GluCEST obtained from a rat brain following middle cerebral artery occlusion (MCAO) stroke showed significant differences between ipsilateral and contralateral sides (Fig. 3e-h ). The ipsilateral side demonstrated an ~100% increase in GluCEST at 4.5 h after MCAO (Fig. 3h) . The z-spectral asymmetry plots from the MCAO brain reported here showed an elevation of CEST, whereas z-spectra from a previously reported MCAO study in the rat brain 18 have shown decreased amide proton CEST effects from the ipsilateral side compared with the contralateral side (Fig. 3i,j) . In addition, amide proton CEST asymmetry plots have shown negative values at 3 p.p.m. 18 , whereas our GluCEST showed positive values. This is because of key differences in the amide proton CEST and GluCEST experimental conditions. Because of low exchange rates (~30 s -1 ) in amide proton CEST, a lower saturation pulse amplitude (root mean square B 1 (B 1rms ) = 50 Hz (1.2 µT)) and longer duration (~6 s) were used in the earlier study. However, owing to the higher glutamate exchange rate, higher B 1rms and shorter duration were used in this study (B 1rms = 155 Hz (3.6 µT) and 1 s).
Literature studies have shown that in the MCAO model of ischemia, extracellular glutamate levels (~1-2 µM basal value) 26 increase substantially to ~0.2 mM (ref. 27 ). However, the total glutamate concentration (extracellular and intracellular) may remain unaltered. In addition, although extracellular concentrations (in µM) of other molecules such as GABA, aspartate, adenosine and taurine also increase 28 , their concentration changes are too small to account for the observed GluCEST effects.
In the MCAO model, it is also well established that the magnitude of pH decrease expected over a 4-h period is ~0.5 units 18 . In addition to pH, other factors that potentially affect GluCEST during stroke are changes to the water content, water spin-spin relaxation time (T 2 ) and magnetization transfer ratio (MTR). It has been reported that in npg the MCAO model, the T 2 of water is elevated by ~20 to 40%, MTR is reduced by ~20% and total water content may be changed by ~2 to 4% 18, 29 . These changes in T 2 , MTR and water content are expected to account for only minor changes in GluCEST.
In polypeptide solutions in PBS, the CEST effect from amine and amide protons has been shown to decrease with decreasing pH in the pH 7.3-5.0 range 30 . In contrast, GluCEST increased here by almost 100% during MCAO ischemia. This increase in GluCEST is consistent with the pH-dependent GluCEST behavior observed in glutamate phantoms at physiological concentrations and temperature, and it suggests that the elevated GluCEST in the ipsilateral side of MCAO model is predominantly because of lower pH.
In healthy brain, glutamate does not cross the blood-brain barrier (BBB); however, the compromised BBB in a tumor model provides a means of demonstrating glutamate modulation, where GluCEST should change approximately linearly with the concentration of glutamate. To demonstrate that the GluCEST measured in vivo is specific to glutamate, we performed GluCEST and 1 H MRS studies in a rat brain with a tumor before and after the intravenous injection of glutamate solution (Fig. 4a-f) . GluCEST maps obtained at three time points after injection showed that there was a notable increase in GluCEST in the tumor, with a concomitant similar elevation in the 1 H MRS of glutamate.
In vivo human brain study A GluCEST map obtained from a healthy human brain (Fig. 5) showed a gray matter and white matter distribution pattern similar to a published positron emission tomography (PET) map of the metabotropic glutamate receptor subtype 5 (mGluR5) (Fig. 5c and  ref. 31) . Concentrations of glutamate derived from the 1 H MRS data (5.9 ± 0.5 mM for white matter and 9.4 ± 1.4 mM for gray matter) were also consistent with the GluCEST from the same regions of interest (ROIs) (Fig. 5a,b,f) .
In human brain, the gray matter and white matter GluCEST contrast was the highest at a saturation pulse length of ~1 s (Fig. 5g) . The z-spectra and CEST asymmetry curves from gray matter and white matter regions of the brain were rather broad and showed a maximum CEST contrast at ~2 p.p.m. (Fig. 5i,j) . The broadness in asymmetry plots may be partly due to (i) the glutamate exchange-induced chemical shift averaging effect that shifts the line toward water resonance and (ii) an additional potential contribution from creatine 32 . Similar results were observed in three volunteers. The intrasubject coefficient of variation of measured GluCEST was <5%.
The GluCEST maps obtained in healthy human brain reflected the known regional variation of physiological concentrations of glutamate 33, 34 . Because 1 H MRS data are highly specific to the concentration of glutamate, the observed strong correlation between GluCEST ratio from gray matter and white matter ROIs (1.6 ± 0.2) with the glutamate concentration ratio from 1 H MRS data in the same ROIs (1.6 ± 0.1) provided additional confirmation that the observed GluCEST in the human brain is predominantly due to glutamate. We estimate that ~70-75% of the observed GluCEST was from glutamate (Supplementary Table 1 ).
DISCUSSION
These findings provide what is to our knowledge the first evidence that GluCEST can be used for noninvasive imaging of glutamate concentrations, with excellent spatial and temporal resolution. In addition to its role as the predominant excitatory neurotransmitter in the brain, glutamate also serves as a metabolic intermediate, and it is likely that GluCEST detects both of these pools.
Although the gray matter to white matter GluCEST contrast ratio in humans, as well as in healthy rat brains, is very similar (~1.6 ± 0.2), the GluCEST magnitude in the rat brain is higher than that in the human brain because of higher strength magnetic fields (9.4T in rats versus 7T in humans), continuous saturation pulses used on rats (constrained by the scanner software) and lower direct water saturation at 9.4T in rats compared with 7T in humans. Because of the fast exchange rate of glutamate amine protons, the slow to intermediate exchange rate condition is not fulfilled at lower-field wholebody clinical scanners (≤3T), and, hence, these studies are expected to have poor sensitivity at these fields.
Potential contributions of MTR asymmetry to GluCEST, caused by the bound pool of water from rigid macromolecules in biological tissues, cannot be excluded. MTR asymmetry effects 35 , if any, would compete with the GluCEST effect and would lead to an underestimation of actual GluCEST levels. Indeed, the simulated MTR asymmetry (−0.14% in gray matter and −0.22% in white matter) (Supplementary Table 1 and Supplementary Discussion) indicates that its contribution to the observed GluCEST is likely to be negligibly small.
Here SAR issues at 7T limit the observed GluCEST sensitivity in humans. However, saturation pulse power, duration, pulse shapes and readout sequences, in conjunction with multichannel RF coils, could be further optimized to enhance GluCEST effects within npg FDA guidelines for SAR deposition. The glutamate contribution to GluCEST may have slight variations per site, depending on the RF coil or static field strength used, and future work should evaluate these contributions for specific experimental conditions. Studies at ultrahigh fields beyond 7T would further enhance the sensitivity of GluCEST, albeit with additional challenges in dealing with SAR deposition. For proof-of-principle purposes, we used only a single slice with a two-dimensional imaging sequence. However, it would be relatively straightforward to implement a three-dimensional acquisition of GluCEST maps.
In summary, GluCEST detection is feasible in the human brain at ultrahigh field (7T) without exceeding the allowed limits on SAR. About 70-75% of the observed CEST is from glutamate, with the remaining 25-30% coming from creatine, GABA and other macromolecules. Despite small contamination from other molecules in vivo, the GluCEST method can be used to study relative changes in glutamate through endogenous or exogenous glutamate modulation in vivo. This method provides noninvasive, nonradioactive and high spatial and temporal resolution imaging of relative changes in glutamate for use in both human subjects and preclinical models. Further, the exquisite sensitivity of GluCEST to changes in pH could potentially be used as a pH marker in evolving stroke and tumors. Future studies using this approach may provide new insights into glutamate function and demonstrate its potential as a biomarker for the diagnosis and treatment of CNS disorders.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
